{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:37:03Z","timestamp":1788550623953,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Atypical femur fracture (AFF) is a rare but catastrophic adverse event first reported in the long-term use of alendronate, one of the most commonly used drugs for osteoporosis currently. However, further evidence is needed to learn more regarding other common anti-osteoporosis drugs and the risk for AFF. In this study, reports of AFF were identified from Food and Drug Administration Adverse Event Reporting System database. Disproportionality analyses were performed to examine the reporting odds ratio (ROR), information component (IC) and adjusted ROR (adj. ROR) signals for AFF for common anti-osteoporosis drugs. A total of 1692 unique AFF reports were identified. The disproportionality signals (the lower bound of 95% confidence interval\u2009&gt;\u20091 for ROR and adjusted ROR, and\u2009&gt;\u20090 for IC) were detected for alendronate, denosumab, pamidronate, risedronate, zoledronate, ibandronate, and teriparatide while no signal was detected for raloxifene, abaloparatide, and romosozumab. When restricted in patients with osteoporosis, the disproportionality signals were still detected for alendronate, pamidronate, risedronate, denosumab, and ibandronate. Our results suggest that alendronate has the largest risk signal, while the risks varied among different bisphosphonates. In addition, denosumab was found statistically associated with AFF in both the entire database and patients with osteoporosis.<\/jats:p>","DOI":"10.1038\/s41598-023-37944-x","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T07:08:26Z","timestamp":1688540906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system"],"prefix":"10.1038","volume":"13","author":[{"given":"Yao","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"37944_CR1","doi-asserted-by":"publisher","unstructured":"Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 94, 646-650 (1993). https:\/\/doi.org\/10.1016\/0002-9343(93)90218-e","DOI":"10.1016\/0002-9343(93)90218-e"},{"key":"37944_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1186\/s12889-016-3712-7","volume":"16","author":"P Chen","year":"2016","unstructured":"Chen, P., Li, Z. & Hu, Y. Prevalence of osteoporosis in China: A meta-analysis and systematic review. BMC Public Health 16, 1039. https:\/\/doi.org\/10.1186\/s12889-016-3712-7 (2016).","journal-title":"BMC Public Health"},{"key":"37944_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/joim.12586","volume":"281","author":"M Katsoulis","year":"2017","unstructured":"Katsoulis, M. et al. Excess mortality after hip fracture in elderly persons from Europe and the USA: The CHANCES project. J. Intern. Med. 281, 300\u2013310. https:\/\/doi.org\/10.1111\/joim.12586 (2017).","journal-title":"J. Intern. Med."},{"key":"37944_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/s0140-6736(21)02646-5","volume":"399","author":"IR Reid","year":"2022","unstructured":"Reid, I. R. & Billington, E. O. Drug therapy for osteoporosis in older adults. Lancet 399, 1080\u20131092. https:\/\/doi.org\/10.1016\/s0140-6736(21)02646-5 (2022).","journal-title":"Lancet"},{"key":"37944_CR5","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina, C. V. et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90, 1294\u20131301. https:\/\/doi.org\/10.1210\/jc.2004-0952 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"37944_CR6","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMc062268","volume":"355","author":"R Armamento-Villareal","year":"2006","unstructured":"Armamento-Villareal, R., Napoli, N., Panwar, V. & Novack, D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N. Engl. J. Med. 355, 2048\u20132050. https:\/\/doi.org\/10.1056\/NEJMc062268 (2006).","journal-title":"N. Engl. J. Med."},{"key":"37944_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane, E. et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 29, 1\u201323. https:\/\/doi.org\/10.1002\/jbmr.1998 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"37944_CR8","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1530\/eje-17-1002","volume":"178","author":"RA Adler","year":"2018","unstructured":"Adler, R. A. Management of endocrine disease: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. Eur. J. Endocrinol. 178, R81\u2013R87. https:\/\/doi.org\/10.1530\/eje-17-1002 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"37944_CR9","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha, S., Wang, Z., Laucis, N. & Bhattacharyya, T. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996\u20132012: An ecological analysis. J. Bone Miner. Res. 30, 2179\u20132187. https:\/\/doi.org\/10.1002\/jbmr.2565 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"37944_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1210\/er.2018-00001","volume":"40","author":"DM Black","year":"2019","unstructured":"Black, D. M., Abrahamsen, B., Bouxsein, M. L., Einhorn, T. & Napoli, N. Atypical femur fractures: Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr. Rev. 40, 333\u2013368. https:\/\/doi.org\/10.1210\/er.2018-00001 (2019).","journal-title":"Endocr. Rev."},{"key":"37944_CR11","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane, E. et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 25, 2267\u20132294. https:\/\/doi.org\/10.1002\/jbmr.253 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"37944_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black, D. M. et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N. Engl. J. Med. 383, 743\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1916525 (2020).","journal-title":"N. Engl. J. Med."},{"key":"37944_CR13","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/jbmr.3221","volume":"32","author":"ES LeBlanc","year":"2017","unstructured":"LeBlanc, E. S. et al. Evaluating atypical features of femur fractures: How change in radiological criteria influenced incidence and demography of atypical femur fractures in a community setting. J. Bone Miner. Res. 32, 2304\u20132314. https:\/\/doi.org\/10.1002\/jbmr.3221 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"37944_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","volume":"85","author":"JC Lo","year":"2016","unstructured":"Lo, J. C. et al. The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 85, 142\u2013147. https:\/\/doi.org\/10.1016\/j.bone.2016.01.002 (2016).","journal-title":"Bone"},{"key":"37944_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00198-015-3355-z","volume":"27","author":"J Selga","year":"2016","unstructured":"Selga, J., Nu\u00f1ez, J. H., Minguell, J., Lalanza, M. & Garrido, M. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: Case report and literature review. Osteoporos. Int. 27, 827\u2013832. https:\/\/doi.org\/10.1007\/s00198-015-3355-z (2016).","journal-title":"Osteoporos. Int."},{"key":"37944_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513\u2013523. https:\/\/doi.org\/10.1016\/s2213-8587(17)30138-9 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"37944_CR17","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/jbmr.4284","volume":"36","author":"S Papapoulos","year":"2021","unstructured":"Papapoulos, S. et al. Incidence of hip and subtrochanteric\/femoral shaft fractures in postmenopausal women with osteoporosis in the phase 3 long-term odanacatib fracture trial. J. Bone Miner. Res. 36, 1225\u20131234. https:\/\/doi.org\/10.1002\/jbmr.4284 (2021).","journal-title":"J. Bone Miner. Res."},{"key":"37944_CR18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948 (2016).","journal-title":"N. Engl. J. Med."},{"key":"37944_CR19","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. 377, 1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322 (2017).","journal-title":"N. Engl. J. Med."},{"key":"37944_CR20","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","volume":"379","author":"MM Dhodapkar","year":"2022","unstructured":"Dhodapkar, M. M. et al. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008\u201319: cross sectional study. BMJ 379, e071752. https:\/\/doi.org\/10.1136\/bmj-2022-071752 (2022).","journal-title":"BMJ"},{"key":"37944_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"HJ Duggirala","year":"2016","unstructured":"Duggirala, H. J. et al. Use of data mining at the food and drug administration. J. Am. Med. Inform. Assoc. 23, 428\u2013434. https:\/\/doi.org\/10.1093\/jamia\/ocv063 (2016).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"37944_CR22","doi-asserted-by":"publisher","first-page":"e13331","DOI":"10.1111\/ijcp.13331","volume":"73","author":"L Meng","year":"2019","unstructured":"Meng, L. et al. Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system. Int J Clin Pract 73, e13331. https:\/\/doi.org\/10.1111\/ijcp.13331 (2019).","journal-title":"Int J Clin Pract"},{"key":"37944_CR23","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.3389\/fphar.2022.967017","volume":"13","author":"S Xia","year":"2022","unstructured":"Xia, S. et al. Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study. Front. Pharmacol. 13, 9617. https:\/\/doi.org\/10.3389\/fphar.2022.967017 (2022).","journal-title":"Front. Pharmacol."},{"key":"37944_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2106\/jbjs.K.01181","volume":"95","author":"BJ Edwards","year":"2013","unstructured":"Edwards, B. J. et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: A systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J. Bone Jt. Surg. Am. 95, 297\u2013307. https:\/\/doi.org\/10.2106\/jbjs.K.01181 (2013).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"37944_CR25","doi-asserted-by":"publisher","unstructured":"Guthrie, A., Fairman, K. & Gerber, D. K. Fractured Timelines: Reporting Patterns for Bisphosphonate-Associated Atypical Fractures and Implications for Postmarket Surveillance. Sr. Care Pharm. 37, 555\u2013564 (2022). https:\/\/doi.org\/10.4140\/TCP.n.2022.555","DOI":"10.4140\/TCP.n.2022.555"},{"key":"37944_CR26","doi-asserted-by":"publisher","unstructured":"Hung, E., Hauben, M., Essex, H., Zou, C. & Bright, S. More extreme duplication in FAERS detected by literature reference normalization and fuzzy string matching. Pharmacoepidemiol. Drug Saf. (2022). https:\/\/doi.org\/10.1002\/pds.5555","DOI":"10.1002\/pds.5555"},{"key":"37944_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10030420","author":"MA Khaleel","year":"2022","unstructured":"Khaleel, M. A., Khan, A. H., Ghadzi, S. M. S., Adnan, A. S. & Abdallah, Q. M. A standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel) https:\/\/doi.org\/10.3390\/healthcare10030420 (2022).","journal-title":"Healthcare (Basel)"},{"key":"37944_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab209","author":"A Goldman","year":"2021","unstructured":"Goldman, A. et al. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. Eur. J. Prev. Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwab209 (2021).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"37944_CR29","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucl. Acids Res. 46, D1074-d1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037 (2018).","journal-title":"Nucl. Acids Res."},{"key":"37944_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"37944_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate, A. & Evans, S. J. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug. Saf. 18, 427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742 (2009).","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"37944_CR32","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol 19, 1579\u20131589. https:\/\/doi.org\/10.1016\/s1470-2045(18)30608-9 (2018).","journal-title":"Lancet Oncol"},{"key":"37944_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C. & Schoretsanitis, G. Post-marketing safety concerns with esketamine: A disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother Psychosom 90, 41\u201348. https:\/\/doi.org\/10.1159\/000510703 (2021).","journal-title":"Psychother Psychosom"},{"key":"37944_CR34","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman, A. et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J. Am. Coll. Cardiol. 78, 1800\u20131813. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.044 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"37944_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler, R. A. et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for bone and mineral research. J Bone Miner Res 31, 16\u201335. https:\/\/doi.org\/10.1002\/jbmr.2708 (2016).","journal-title":"J Bone Miner Res"},{"key":"37944_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12603-015-0652-3","volume":"21","author":"KS Khow","year":"2017","unstructured":"Khow, K. S., Shibu, P., Yu, S. C., Chehade, M. J. & Visvanathan, R. Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: A systematic review. J. Nutr. Health Aging 21, 83\u201391. https:\/\/doi.org\/10.1007\/s12603-015-0652-3 (2017).","journal-title":"J. Nutr. Health Aging"},{"key":"37944_CR37","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell, R. et al. Pharmacological management of osteoporosis in postmenopausal women: An endocrine society* clinical practice guideline. J. Clin. Endocrinol. Metab. 104, 1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"37944_CR38","doi-asserted-by":"publisher","unstructured":"Wells, G. A. et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Coch. Database Syst. Rev. 5, Cd004523 (2022). https:\/\/doi.org\/10.1002\/14651858.CD004523.pub4","DOI":"10.1002\/14651858.CD004523.pub4"},{"key":"37944_CR39","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","volume":"172","author":"RPH Meier","year":"2012","unstructured":"Meier, R. P. H., Perneger, T. V., Stern, R., Rizzoli, R. & Peter, R. E. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch. Internal Med. 172, 930\u2013936. https:\/\/doi.org\/10.1001\/archinternmed.2012.1796 (2012).","journal-title":"Arch. Internal Med."},{"key":"37944_CR40","first-page":"39","volume":"33","author":"G Cleto-Zepeda","year":"2019","unstructured":"Cleto-Zepeda, G., Dur\u00e1n-Mart\u00ednez, N. & Tena-Sanabria, M. E. Atypical femoral fracture, case report and literature review. Acta Ortop Mex 33, 39\u201341 (2019).","journal-title":"Acta Ortop Mex"},{"key":"37944_CR41","doi-asserted-by":"publisher","first-page":"101091","DOI":"10.1016\/j.bonr.2021.101091","volume":"14","author":"F Hirano","year":"2021","unstructured":"Hirano, F. et al. Disturbance of osteonal bone remodeling and high tensile stresses on the lateral cortex in atypical femoral fracture after long-term treatment with Risedronate and Alfacalcidol for osteoporosis. Bone Rep 14, 101091. https:\/\/doi.org\/10.1016\/j.bonr.2021.101091 (2021).","journal-title":"Bone Rep"},{"key":"37944_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bcr-2016-217489","volume":"2017","author":"R Espey","year":"2017","unstructured":"Espey, R., Grimes, S., Heyburn, G. & Kealey, W. D. The first reported case of Atypical Femoral Fracture caused by daily ibandronate prescribed for bone metastases in breast cancer. BMJ Case Rep. 2017, 1. https:\/\/doi.org\/10.1136\/bcr-2016-217489 (2017).","journal-title":"BMJ Case Rep."},{"key":"37944_CR43","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00198-019-05227-9","volume":"31","author":"N Nasomyont","year":"2020","unstructured":"Nasomyont, N., Hornung, L. N. & Wasserman, H. Intravenous bisphosphonate therapy in children with spinal muscular atrophy. Osteoporos. Int. 31, 995\u20131000. https:\/\/doi.org\/10.1007\/s00198-019-05227-9 (2020).","journal-title":"Osteoporos. Int."},{"key":"37944_CR44","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/bpo.0000000000000552","volume":"36","author":"A Hegazy","year":"2016","unstructured":"Hegazy, A. et al. Unusual femur stress fractures in children with osteogenesis imperfecta and intramedullary rods on long-term intravenous pamidronate therapy. J. Pediatr. Orthop. 36, 757\u2013761. https:\/\/doi.org\/10.1097\/bpo.0000000000000552 (2016).","journal-title":"J. Pediatr. Orthop."},{"key":"37944_CR45","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jocd.2012.03.003","volume":"15","author":"F Alshahrani","year":"2012","unstructured":"Alshahrani, F. & Kendler, D. Femoral fractures in osteoporotic patients on bisphosphonates. A case report. J. Clin. Densitom. 15, 380\u2013384. https:\/\/doi.org\/10.1016\/j.jocd.2012.03.003 (2012).","journal-title":"J. Clin. Densitom."},{"key":"37944_CR46","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/jbmr.2818","volume":"31","author":"BJ Edwards","year":"2016","unstructured":"Edwards, B. J. et al. Incidence of atypical femur fractures in cancer patients: The MD anderson cancer center experience. J. Bone Miner. Res. 31, 1569\u20131576. https:\/\/doi.org\/10.1002\/jbmr.2818 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"37944_CR47","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2106\/jbjs.J.01199","volume":"93","author":"ME Puhaindran","year":"2011","unstructured":"Puhaindran, M. E. et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J. Bone Jt. Surg. Am. 93, 1235\u20131242. https:\/\/doi.org\/10.2106\/jbjs.J.01199 (2011).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"37944_CR48","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12282-016-0746-8","volume":"24","author":"S Ota","year":"2017","unstructured":"Ota, S. et al. Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis. Breast Cancer 24, 601\u2013607. https:\/\/doi.org\/10.1007\/s12282-016-0746-8 (2017).","journal-title":"Breast Cancer"},{"key":"37944_CR49","doi-asserted-by":"publisher","first-page":"12290","DOI":"10.1038\/s41598-022-15941-w","volume":"12","author":"Y Pan","year":"2022","unstructured":"Pan, Y. et al. Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries. Sci. Rep. 12, 12290. https:\/\/doi.org\/10.1038\/s41598-022-15941-w (2022).","journal-title":"Sci. Rep."},{"key":"37944_CR50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1359\/jbmr.081112","volume":"24","author":"PJ Kostenuik","year":"2009","unstructured":"Kostenuik, P. J. et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL. J. Bone Miner. Res. 24, 182\u2013195. https:\/\/doi.org\/10.1359\/jbmr.081112 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"37944_CR51","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/s0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston, J. E., McClung, M. R. & Leslie, W. D. Osteoporosis. Lancet 393, 364\u2013376. https:\/\/doi.org\/10.1016\/s0140-6736(18)32112-3 (2019).","journal-title":"Lancet"},{"key":"37944_CR52","doi-asserted-by":"publisher","first-page":"e3366","DOI":"10.1210\/clinem\/dgac262","volume":"107","author":"H Lyu","year":"2022","unstructured":"Lyu, H. et al. Denosumab and risk of community-acquired pneumonia: A population-based cohort study. J. Clin. Endocrinol. Metab. 107, e3366\u2013e3373. https:\/\/doi.org\/10.1210\/clinem\/dgac262 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"37944_CR53","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/17453674.2016.1277412","volume":"88","author":"DC Austin","year":"2017","unstructured":"Austin, D. C., Torchia, M. T., Klare, C. M. & Cantu, R. V. Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab. Acta Orthop. 88, 351\u2013353. https:\/\/doi.org\/10.1080\/17453674.2016.1277412 (2017).","journal-title":"Acta Orthop."},{"key":"37944_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","volume":"16","author":"J Starr","year":"2018","unstructured":"Starr, J., Tay, Y. K. D. & Shane, E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr. Osteoporos. Rep. 16, 519\u2013529. https:\/\/doi.org\/10.1007\/s11914-018-0464-6 (2018).","journal-title":"Curr. Osteoporos. Rep."},{"key":"37944_CR55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings, S. R. et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Miner. Res. 33, 190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"37944_CR56","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt, P., Faouzi, M., Buclin, T. & Lamy, O. Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases. J. Bone Miner. Res. 36, 1717\u20131728. https:\/\/doi.org\/10.1002\/jbmr.4335 (2021).","journal-title":"J. Bone Miner. Res."},{"key":"37944_CR57","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/m20-0882","volume":"173","author":"H Lyu","year":"2020","unstructured":"Lyu, H. et al. Delayed denosumab injections and fracture risk among patients with osteoporosis: A population-based cohort study. Ann. Intern Med. 173, 516\u2013526. https:\/\/doi.org\/10.7326\/m20-0882 (2020).","journal-title":"Ann. Intern Med."},{"key":"37944_CR58","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder, B. Z. et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet 386, 1147\u20131155. https:\/\/doi.org\/10.1016\/s0140-6736(15)61120-5 (2015).","journal-title":"Lancet"},{"key":"37944_CR59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1210\/endrev\/bnab005","volume":"42","author":"TJ Martin","year":"2021","unstructured":"Martin, T. J., Sims, N. A. & Seeman, E. Physiological and pharmacological roles of PTH and PTHrP in bone using their shared receptor, PTH1R. Endocr. Rev. 42, 383\u2013406. https:\/\/doi.org\/10.1210\/endrev\/bnab005 (2021).","journal-title":"Endocr. Rev."},{"key":"37944_CR60","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1210\/jc.2010-2520","volume":"96","author":"SJ Gomberg","year":"2011","unstructured":"Gomberg, S. J., Wustrack, R. L., Napoli, N., Arnaud, C. D. & Black, D. M. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J. Clin. Endocrinol. Metab. 96, 1627\u20131632. https:\/\/doi.org\/10.1210\/jc.2010-2520 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"37944_CR61","doi-asserted-by":"publisher","first-page":"333","DOI":"10.18926\/amo\/63744","volume":"76","author":"M Akagawa","year":"2022","unstructured":"Akagawa, M. et al. Successful treatment of atypical femoral fracture with bowed femur using contralateral intramedullary nail combined with early daily teriparatide. Acta Med. Okayama 76, 333\u2013338. https:\/\/doi.org\/10.18926\/amo\/63744 (2022).","journal-title":"Acta Med. Okayama"},{"key":"37944_CR62","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00198-017-4286-7","volume":"29","author":"SL Greenspan","year":"2018","unstructured":"Greenspan, S. L. et al. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. Osteoporos. Int. 29, 501\u2013506. https:\/\/doi.org\/10.1007\/s00198-017-4286-7 (2018).","journal-title":"Osteoporos. Int."},{"key":"37944_CR63","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00198-018-4658-7","volume":"29","author":"H Tsuchie","year":"2018","unstructured":"Tsuchie, H. et al. The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: Comparison between daily and weekly administration. Osteoporos Int. 29, 2659\u20132665. https:\/\/doi.org\/10.1007\/s00198-018-4658-7 (2018).","journal-title":"Osteoporos Int."},{"key":"37944_CR64","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1105\/jbm.2015.22.4.183","volume":"22","author":"GI Im","year":"2015","unstructured":"Im, G. I. & Lee, S. H. Effect of teriparatide on healing of atypical femoral fractures: A systemic review. J. Bone Metab. 22, 183\u2013189. https:\/\/doi.org\/10.1105\/jbm.2015.22.4.183 (2015).","journal-title":"J. Bone Metab."},{"key":"37944_CR65","doi-asserted-by":"publisher","first-page":"115319","DOI":"10.1016\/j.bone.2020.115319","volume":"135","author":"HH Nguyen","year":"2020","unstructured":"Nguyen, H. H. et al. Asian ethnicity is associated with atypical femur fractures in an Australian population study. Bone 135, 115319. https:\/\/doi.org\/10.1016\/j.bone.2020.115319 (2020).","journal-title":"Bone"},{"key":"37944_CR66","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1056\/NEJMc0910389","volume":"362","author":"CM Girgis","year":"2010","unstructured":"Girgis, C. M., Sher, D. & Seibel, M. J. Atypical femoral fractures and bisphosphonate use. N. Engl. J. Med. 362, 1848\u20131849. https:\/\/doi.org\/10.1056\/NEJMc0910389 (2010).","journal-title":"N. Engl. J. Med."},{"key":"37944_CR67","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","volume":"86","author":"J Schilcher","year":"2015","unstructured":"Schilcher, J., Koeppen, V., Aspenberg, P. & Micha\u00eblsson, K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 86, 100\u2013107. https:\/\/doi.org\/10.3109\/17453674.2015.1004149 (2015).","journal-title":"Acta Orthop"},{"key":"37944_CR68","doi-asserted-by":"publisher","first-page":"i3365","DOI":"10.1136\/bmj.i3365","volume":"353","author":"B Abrahamsen","year":"2016","unstructured":"Abrahamsen, B., Eiken, P., Prieto-Alhambra, D. & Eastell, R. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 353, i3365. https:\/\/doi.org\/10.1136\/bmj.i3365 (2016).","journal-title":"BMJ"},{"key":"37944_CR69","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","volume":"364","author":"J Schilcher","year":"2011","unstructured":"Schilcher, J., Micha\u00eblsson, K. & Aspenberg, P. Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J. Med. 364, 1728\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1010650 (2011).","journal-title":"N. Engl. J. Med."},{"key":"37944_CR70","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1210\/jc.2012-1896","volume":"98","author":"N Napoli","year":"2013","unstructured":"Napoli, N. et al. Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. J. Clin. Endocrinol. Metab. 98, 659\u2013667. https:\/\/doi.org\/10.1210\/jc.2012-1896 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"37944_CR71","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/17453674.2014.885355","volume":"85","author":"J Schilcher","year":"2014","unstructured":"Schilcher, J. & Aspenberg, P. Atypical fracture of the femur in a patient using denosumab\u2013a case report. Acta Orthop. 85, 6\u20137. https:\/\/doi.org\/10.3109\/17453674.2014.885355 (2014).","journal-title":"Acta Orthop."},{"key":"37944_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/17453674.2013.854668","volume":"85","author":"E Drampalos","year":"2014","unstructured":"Drampalos, E., Skarpas, G., Barbounakis, N. & Michos, I. Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop. 85, 3\u20135. https:\/\/doi.org\/10.3109\/17453674.2013.854668 (2014).","journal-title":"Acta Orthop."},{"key":"37944_CR73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00223-022-00952-6","volume":"111","author":"JKM Goh","year":"2022","unstructured":"Goh, J. K. M., Koh, J. S. B., Ng, A. C. M., Png, M. A. & Howe, T. S. Bilateral atypical femur fractures after denosumab in a bisphosphonate naive patient: A case report. Calcif. Tissue Int. 111, 96\u2013101. https:\/\/doi.org\/10.1007\/s00223-022-00952-6 (2022).","journal-title":"Calcif. Tissue Int."},{"key":"37944_CR74","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bone.2013.12.027","volume":"61","author":"RN Thompson","year":"2014","unstructured":"Thompson, R. N., Armstrong, C. L. & Heyburn, G. Bilateral atypical femoral fractures in a patient prescribed denosumab\u2014A case report. Bone 61, 44\u201347. https:\/\/doi.org\/10.1016\/j.bone.2013.12.027 (2014).","journal-title":"Bone"},{"key":"37944_CR75","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1177\/0192623317737066","volume":"45","author":"JP Brown","year":"2017","unstructured":"Brown, J. P. Antiresorptives: Safety concerns-clinical perspective. Toxicol Pathol 45, 859\u2013863. https:\/\/doi.org\/10.1177\/0192623317737066 (2017).","journal-title":"Toxicol Pathol"},{"key":"37944_CR76","doi-asserted-by":"publisher","first-page":"e10681","DOI":"10.1002\/jbm4.10681","volume":"6","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber, J. et al. Incidence of atypical femoral fractures in patients on osteoporosis therapy\u2014A registry-based cohort study. JBMR Plus 6, e10681. https:\/\/doi.org\/10.1002\/jbm4.10681 (2022).","journal-title":"JBMR Plus"},{"key":"37944_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15010240","volume":"15","author":"S Xia","year":"2023","unstructured":"Xia, S. et al. Association of pulmonary sepsis and immune checkpoint inhibitors: A pharmacovigilance study. Cancers 15, 1. https:\/\/doi.org\/10.3390\/cancers15010240 (2023).","journal-title":"Cancers"},{"key":"37944_CR78","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","volume":"20","author":"BM Bonora","year":"2021","unstructured":"Bonora, B. M., Raschi, E., Avogaro, A. & Fadini, G. P. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovasc Diabetol 20, 39. https:\/\/doi.org\/10.1186\/s12933-021-01243-4 (2021).","journal-title":"Cardiovasc Diabetol"},{"key":"37944_CR79","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-021-00625-4","volume":"22","author":"PM Jedlowski","year":"2021","unstructured":"Jedlowski, P. M., Jedlowski, M. F. & Fazel, M. T. DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: A pharmacovigilance study of the FDA adverse event reporting system (FAERS) from 2006 to 2020. Am J Clin Dermatol 22, 891\u2013900. https:\/\/doi.org\/10.1007\/s40257-021-00625-4 (2021).","journal-title":"Am J Clin Dermatol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37944-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37944-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37944-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T07:15:33Z","timestamp":1688541333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37944-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37944"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-37944-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"11 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10892"}}